Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations
Moderna (MRNA) shares dropped 25% despite positive cancer vaccine data, which reduced melanoma recurrence or death risk by 42% in certain patients. The stock remains up 530% in 2026. Analysts attribute the selloff to high expectations. The vaccine, paired with Merck's Keytruda, showed 82% of patients alive without recurrence at two years. Full phase 3 results are pending.
How this was made
The 30-second read
Why it matters
The unexpected efficacy numbers triggered a 25% share decline, reflecting market disappointment and concerns over manufacturing scalability.
Market read
First disclosure of trial data creates immediate trading opportunity on Moderna's stock.
What to watch
Manufacturing lead times and sequencing costs could limit commercial upside despite efficacy.
Background
Moderna announced partial Phase 2 data for its personalized melanoma vaccine combined with Merck's Keytruda, showing a 42% risk reduction.
Ticker impact
Moderna's cancer vaccine trial data showed a 42% reduction in melanoma recurrence or death risk, prompting a 25% share drop.
likely further pressure as the market prices in the weaker-than‑expected efficacy data
The data were leaked as the first public disclosure and immediately moved the stock 25% lower, suggesting traders will continue to react.
Market effects
May dampen enthusiasm for personalized cancer vaccine platforms across biotech.
Limited to US biotech equities; no broader regional effect.
Highlights risk in oncology trial outcomes for global investors.
Counterpoint
If the data are only partial, later full results could exceed expectations and trigger a rebound.
Key entities
- CompanyModerna
Biotech firm developing personalized cancer vaccines.
- CompanyMerck
Partner providing Keytruda immunotherapy.
